Commentary: Evaluating Potential Glioma Serum Biomarkers, with Future Applications

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2022 Jun 6

PMID 35662986

Authors

Michael Goutnik

Brandon Lucke-Wold

Affiliations

Soon will be listed here.

Abstract

Systemic inflammation within malignant glioma is a topic of ongoing significance. In this commentary, we highlight recent findings from Gandhi and discuss alternative approaches. We present a counter argument with findings that IL-6 markers are controversial. We highlight the potential benefit of looking at microRNAs and other biomarkers. Finally, we present ideas for future application involving differentiation between radiation necrosis and recurrence. The commentary is intended to serve as a catalyst for further scientific discovery.

Citing Articles

Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.

Kino S, Kanamori M, Shimoda Y, Niizuma K, Endo H, Matsuura Y BMC Cancer. 2024; 24(1):222.

PMID: 38365669 PMC: 10870484. DOI: 10.1186/s12885-024-11970-y.

Emerging perspectives on RNA virus-mediated infections: from pathogenesis to therapeutic interventions.

Mohanty P, Panda P, Acharya R, Pande B, Bhaskar L, Verma H World J Virol. 2024; 12(5):242-255.

PMID: 38187500 PMC: 10768389. DOI: 10.5501/wjv.v12.i5.242.

Systematic Review of the Diagnostic and Clinical Utility of Salivary microRNAs in Traumatic Brain Injury (TBI).

Hiskens M, Mengistu T, Li K, Fenning A Int J Mol Sci. 2022; 23(21).

PMID: 36361944 PMC: 9654991. DOI: 10.3390/ijms232113160.

References

Shan Y, He X, Song W, Han D, Niu J, Wang J . Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med. 2015; 8(6):9114-20. PMC: 4538008. View

Ohba S, Mukherjee J, Johannessen T, Mancini A, Chow T, Wood M . Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016; 76(22):6680-6689. PMC: 5290072. DOI: 10.1158/0008-5472.CAN-16-0696. View

Zhang J, Wang P, Ji W, Ding Y, Lu X . Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. Int J Neurosci. 2016; 127(3):210-217. DOI: 10.1080/00207454.2016.1175441. View

Bark J, Kulasinghe A, Chua B, Day B, Punyadeera C . Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2019; 122(3):295-305. PMC: 7000822. DOI: 10.1038/s41416-019-0603-6. View

Gan Y, Zhou X, Niu X, Li J, Wang T, Zhang H . Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas. World Neurosurg. 2019; 127:e261-e267. DOI: 10.1016/j.wneu.2019.03.085. View

Lippitz B . Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14(6):e218-28. DOI: 10.1016/S1470-2045(12)70582-X. View

Wang P, Meng Z, Song H, Yao K, Duan Z, Yu C . Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival. Front Pharmacol. 2018; 9:886. PMC: 6103192. DOI: 10.3389/fphar.2018.00886. View

Bjornbak Holst C, Christensen I, Skjoth-Rasmussen J, Hamerlik P, Poulsen H, Johansen J . Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Front Oncol. 2020; 10:478. PMC: 7180208. DOI: 10.3389/fonc.2020.00478. View

Westphal M, Lamszus K . Circulating biomarkers for gliomas. Nat Rev Neurol. 2015; 11(10):556-66. DOI: 10.1038/nrneurol.2015.171. View

10.

Sultana N, Sun C, Katsube T, Wang B . Biomarkers of Brain Damage Induced by Radiotherapy. Dose Response. 2020; 18(3):1559325820938279. PMC: 7350401. DOI: 10.1177/1559325820938279. View

11.

Lei Y, Li Y, Hu Q, Wang J, Sui A . Prognostic impact of neutrophil-to-lymphocyte ratio in gliomas: a systematic review and meta-analysis. World J Surg Oncol. 2019; 17(1):152. PMC: 6717646. DOI: 10.1186/s12957-019-1686-5. View

12.

Morimura T, Neuchrist C, Kitz K, Budka H, Scheiner O, Kraft D . Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol. 1990; 80(3):287-94. DOI: 10.1007/BF00294647. View

13.

Doroudchi M, Pishe Z, Malekzadeh M, Golmoghaddam H, Taghipour M, Ghaderi A . Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev. 2013; 14(9):5225-30. DOI: 10.7314/apjcp.2013.14.9.5225. View

14.

Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E . Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2010; 102(1):35-41. DOI: 10.1007/s11060-010-0290-x. View

15.

Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H . Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery. 2013; 72(6):1031-8. DOI: 10.1227/NEU.0b013e31828cf945. View

16.

Charles N, Holland E, Gilbertson R, Glass R, Kettenmann H . The brain tumor microenvironment. Glia. 2011; 59(8):1169-80. DOI: 10.1002/glia.21136. View

17.

Auezova R, Ivanova N, Akshulakov S, Zhetpisbaev B, Kozhakhmetova A, Ryskeldiyev N . Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients. Cancer Manag Res. 2019; 11:3227-3236. PMC: 6489560. DOI: 10.2147/CMAR.S195754. View

18.

Parney I, Waldron J, Parsa A . Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg. 2009; 110(3):572-82. PMC: 3064468. DOI: 10.3171/2008.7.JNS08475. View

19.

Hussain S, Yang D, Suki D, Aldape K, Grimm E, Heimberger A . The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006; 8(3):261-79. PMC: 1871955. DOI: 10.1215/15228517-2006-008. View

20.

Fathi A, Nahed B, Wander S, Iafrate A, Borger D, Hu R . Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist. 2016; 21(2):214-9. PMC: 4746092. DOI: 10.1634/theoncologist.2015-0342. View